This parallel group dose-ranging study of MK-0677 in Growth Hormone (GH) Deficient children is part of a multicenter trial to study this oral drug in children with idiopathic GH deficiency. Subjects must be at least 4 years of age, prepubertal, and on GH therapy for at least one year prior to enrollment. Subjects who respond to a single test dose of Mk-0677 will be randomized to receive either one of four daily doses of MK-0677 or continued on GH injections. Growth velocity, IGF-1 and IGFBP-3 levels will be measured as mediators of efficacy. The potential benefit of avoiding daily injections of GH is an important reason for performing this study.
Showing the most recent 10 out of 470 publications